CoChat
Sign Up
Cited by 84

MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer’s disease

Tian, Ning, Cao, Zeyuan, Zhang, Yan·2014·Neuroscience Bulletin
DOI 10.1007/s12264-013-1419-7
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12264-013-1419-7

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MiR-206 is consistently elevated in AD cortex and serum, suppresses BDNF and IGF1, and is associated with synaptic decline and cognitive deficits.

    “MiR-206 is consistently elevated in AD cortex and serum, suppresses BDNF and IGF1, and is associated with synaptic decline and cognitive deficits (Lee et al., 2012; Tian et al., 2014).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Tian et al., 2014

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 47

  1. Price DL, Sisodia SS, Gandy SE. Amyloid beta amyloidosis in Alzheimer's disease. Curr Opin Neurol 1995, 8: 268-274.
  2. Chan AW, Kocerha J. The path to microRNA therapeutics in psychiatric and neurodegenerative disorders. Front Genet 2012, 3: 82.
  3. Delay C, Mandemakers W, Hebert SS. MicroRNAs in Alzheimer's disease. Neurobiol Dis 2012, 46: 285-290.
  4. Delay C, Hebert SS. MicroRNAs and Alzheimer's disease mouse models: Current insights and future research avenues. Int J Alzheimers Dis 2011, 2011: 894938.
  5. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294: 853-858.
  6. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004, 7: 113-117.
  7. Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in Drosophila. Cell 2006, 124: 191-205.
  8. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452: 896-899.
  9. Hollander JA, Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 2010, 466: 197-202.
  10. Peters L, Meister G. Argonaute proteins: mediators of RNA silencing. Mol Cell 2007, 26: 611-623.
  11. Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15: 21-32.
  12. Meister G. miRNAs get an early start on translational silencing. Cell 2007, 131: 25-28.
  13. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med 2011, 13: 217-222.
  14. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008, 59: 201-220.
  15. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4: 299-309.
  16. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361: 1545-1564.
  17. Arancibia S, Silhol M, Mouliere F, Meffre J, Hollinger I, Maurice T, et al. Protective effect of BDNF against beta- amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 2008, 31: 316-326.
  18. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain- derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15: 331-337.
  19. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, et al. beta-Amyloid impairs axonal BDNF retrograde traffi cking. Neurobiol Aging 2011, 32: 821-833.
  20. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased brain-derived neurotrophic Ning Tian, et al. miR-206 decreases BDNF in AD mice 197 factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009, 29: 9321-9329.
  21. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001, 6: 83-86.
  22. Tsai SJ, Hong CJ, Liu HC, Liu TY, Hsu LE, Lin CH. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset. Neuropsychobiology 2004, 49: 10-12.
  23. Tsai SJ, Hong CJ, Liu HC, Liu TY, Liou YJ. The brain- derived neurotrophic factor gene as a possible susceptibility candidate for Alzheimer's disease in a chinese population. Dement Geriatr Cogn Disord 2006, 21: 139-143.
  24. Olin D, MacMurray J, Comings DE. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci Lett 2005, 381: 275-278.
  25. Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, et al. Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. J Neurosci 2011, 31: 16227-16240.
  26. Wang Y, Cui J, Sun X, Zhang Y. Tunneling-nanotube development in astrocytes depends on p53 activation. Cell Death Differ 2011, 18: 732-742.
  27. Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifi ro M, LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. J Neurosci 2004, 24: 5315- 5321.
  28. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002, 156: 519-529.
  29. Cui J, Chen Q, Yue X, Jiang X, Gao GF, Yu LC, et al. Galanin protects against intracellular amyloid toxicity in human primary neurons. J Alzheimers Dis 2010, 19: 529-544.
  30. Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, et al. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 2003, 23: 7385-7394.
  31. Zhang Y, Goodyer C, LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J Neurosci 2000, 20: 8384-8389.
  32. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic--ischemic brain damage. Ann Neurol 1986, 19: 105-111.
  33. Ji Y, Lu Y, Yang F, Shen W, Tang TT, Feng L, et al. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat Neurosci 2010, 13: 302-309.
  34. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations refl ect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011, 14: 347-353.
  35. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, et al. miR- 206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 2012, 72: 269-277.
  36. Chen TJ, Wang DC, Chen SS. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. J Neurosci Res 2009, 87: 2297-2307.
  37. Echeverria V, Berman DE, Arancio O. Oligomers of beta- amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. Curr Alzheimer Res 2007, 4: 518-521.
  38. Wang DC, Chen SS, Lee YC, Chen TJ. Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons. Neurosci Lett 2006, 398: 78-82.
  39. Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J Neurosci 2008, 28: 11760-11767.
  40. Forlenza OV, Diniz BS, Talib LL, Mendonca VA, Ojopi EB, Gattaz WF, et al. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 28: 507-512.
  41. Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonca VA, Gattaz WF, et al. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010, 22: 1305-1311.
  42. Mrak RE. Neuropathology and the neuroinfl ammation idea. J Alzheimers Dis 2009, 18: 473-481.
  43. Shruster A, Melamed E, Offen D. Neurogenesis in the aged and neurodegenerative brain. Apoptosis 2010, 15: 1415- 1421.
  44. Chen Q, Nakajima A, Choi SH, Xiong X, Sisodia SS, Tang YP. Adult neurogenesis is functionally associated with AD-like neurodegeneration. Neurobiol Dis 2008, 29: 316-326.
  45. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011, 198: 351-356.
  46. Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HP, Diniz BS, et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2011, 45: 220-224.
  47. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008, 104: 1433-1439.

Cited by

Sorted by citations

Authors
Tian, N., Cao, Z., & Zhang, Y.
Venue
Neuroscience Bulletin
Publisher
Springer Science and Business Media LLC
Published
2014-03-06
Volume
30
Issue
2
Pages
191-197
ISSN
  • 1673-7067
  • 1995-8218
DOI
10.1007/s12264-013-1419-7
Cited by
84
References
3
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review